secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-08-30T23:59:59+00:00
Accession:  0001104659-22-096092
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE receives Nasdaq extension to Feb 2023; pays Tay £850k for BETi compounds
-----------------------------------------------------------------------------

- Nasdaq granted 180-day extension until Feb 27, 2023 to regain minimum $1.00 bid price for 10 consecutive days.
- VYNE common stock transferred from Nasdaq Global Select to Capital Market, effective Aug 31, 2022.
- VYNE paid Tay Therapeutics £850,000 after receipt of Oral BETi Compounds meeting specified molecular profile.
- Company expects to exercise exclusive option on Oral BETi Compounds by end of 2022, before Feb 28, 2023 expiry.
- If compliance not regained by Feb 27, 2023, Nasdaq will delist; VYNE may appeal or consider reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922096092/0001104659-22-096092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922096092/tm2224821d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-096092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer